How big is Centogene NV?

As of Jun 18, Centogene NV has a market capitalization of 4.27 million, categorizing it as a Micro Cap company. As of Jun 22, it reported net sales of 108.13 million but a net profit of -64.65 million, with shareholder's funds of -27.93 million and total assets of 85.23 million as of Dec 23.

As of Jun 18, Centogene NV has a market capitalization of 4.27 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 22, the company reported net sales of 108.13 million for the latest four quarters. However, it also recorded a net profit of -64.65 million during the same period.<BR><BR>As of Dec 23, the company's balance sheet shows shareholder's funds of -27.93 million and total assets amounting to 85.23 million.

What does Centogene NV do?

Centogene NV is a Germany-based company specializing in rare diseases, converting clinical, genetic, and biochemical data into medical solutions. As of June 2022, it reported net sales of $12 million and a net loss of $13 million, with a market cap of $4.27 million.

Overview: <BR>Centogene NV is a Germany-based company engaged in the rare disease market, focusing on transforming clinical, genetic, and biochemical data into medical solutions for patients, physicians, and pharmaceutical companies. It operates in the micro-cap bracket.<BR><BR>Financial Snapshot: <BR>Net Sales: 12 Million (Quarterly Results - Jun 2022) <BR>Net Profit: -13 Million (Quarterly Results - Jun 2022) <BR>Market cap: USD 4.27 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.93 <BR>Return on Equity: 241.13% <BR>Price to Book: -0.15<BR><BR>Contact Details: <BR>Address: Am Strande 7, ROSTOCK None: 18055 <BR>Tel: ['49 30 213000325'] <BR>Website: https://www.centogene.com/

Should I buy, sell or hold Centogene NV?

Who are in the management team of Centogene NV?

As of March 2022, the management team of Centogene NV includes Dr. Flemming Ornskov (Chairman), Mr. Peer Schatz (Independent Vice Chairman), and several independent members: Dr. Hubert Birner, Mr. Berndt Modig, Mr. Guido Prehn, Dr. Eric Souetre, and Mr. Christoph Ehlers. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Centogene NV includes the following members of the Board of Directors:<BR><BR>- Dr. Flemming Ornskov, Chairman of the Supervisory Board<BR>- Mr. Peer Schatz, Independent Vice Chairman of the Supervisory Board<BR>- Dr. Hubert Birner, Independent Member of the Supervisory Board<BR>- Mr. Berndt Modig, Independent Member of the Supervisory Board<BR>- Mr. Guido Prehn, Independent Member of the Supervisory Board<BR>- Dr. Eric Souetre, Independent Member of the Supervisory Board<BR>- Mr. Christoph Ehlers, Member of the Supervisory Board<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Is Centogene NV overvalued or undervalued?

As of February 10, 2020, Centogene NV is considered risky and overvalued due to severe financial distress, reflected in its negative price-to-book value, negative EV to EBITDA ratio, alarming return on capital employed, and significant underperformance compared to the S&P 500.

As of 10 February 2020, Centogene NV's valuation grade has moved from does not qualify to risky, indicating a significant change in its financial outlook. The company appears to be overvalued given its current financial metrics, with a price to book value of -0.15 and an EV to EBITDA ratio of -1.37, both of which suggest severe financial distress. Additionally, the return on capital employed (ROCE) stands at an alarming -253.34%, highlighting the company's inability to generate returns on its capital.<BR><BR>In comparison to its peers, Centogene NV's P/E ratio is -0.0634, while Candel Therapeutics, Inc. has a P/E of -7.3556, and Gaia, Inc. shows a P/E of -21.7073, indicating that Centogene is not the worst performer among its peers but still reflects a troubling valuation. The company's stock has underperformed significantly over the past year, with a return of -62.53% compared to the S&P 500's gain of 10.26%, reinforcing the notion that Centogene NV is overvalued in its current state.

Is Centogene NV technically bullish or bearish?

As of August 1, 2025, Centogene NV's technical trend has shifted to mildly bearish, indicated by bearish daily moving averages and Bollinger Bands, despite some underlying strength from weekly and monthly MACD and KST, while the stock has performed well in the short term with a 1-week return of 18.80% and a 1-month return of 44.43%, but has a negative year-to-date return of -25.44%.

As of 1 August 2025, the technical trend for Centogene NV has changed from sideways to mildly bearish. The current technical stance is bearish, primarily driven by the daily moving averages indicating bearishness, while the weekly and monthly Bollinger Bands also reflect a mildly bearish outlook. Despite this, the MACD and KST on a weekly and monthly basis are mildly bullish, suggesting some underlying strength. The stock has shown strong short-term performance with a 1-week return of 18.80% compared to the S&P 500's 1.05%, and a 1-month return of 44.43% against the S&P 500's 2.33%. However, longer-term returns are significantly negative, with a year-to-date return of -25.44% versus the S&P 500's 12.22%.